What Happened
Regeneron Pharmaceuticals announced its melanoma drug trial failed to meet its primary endpoint, sending a negative signal through the biotech and pharmaceutical sector. While Regeneron is not directly listed on the ASX, the news has broader implications for healthcare stocks globally, including ASX-listed CSL, which trades in a correlated space. The Nasdaq, heavily weighted toward growth and healthcare names, faces added pressure from this miss at a time when the index is already navigating key technical levels.
Key Levels
Nasdaq (NDX):
- Support 1: 18,800 — recent consolidation floor
- Support 2: 18,400 — April swing low
- Resistance 1: 19,500 — 50-day moving average zone
- Resistance 2: 20,000 — psychological round number and prior breakdown point
CSL (ASX: CSL):
- Support 1: $295.00 — recent demand zone
- Support 2: $285.00 — longer-term structural support
- Resistance 1: $310.00 — 50-day moving average
- Resistance 2: $320.00 — prior consolidation high
Technical Picture
The Nasdaq remains in a short-term downtrend below its 50-day moving average, with RSI hovering near 42 — not yet oversold, suggesting further downside risk is possible before a meaningful bounce. CSL has been underperforming the broader ASX 200 in recent weeks, trading below both its 50-day and 200-day moving averages, which is a bearish signal for trend-following traders.
What Traders Are Watching
For CSL, a daily close below $295.00 would likely accelerate selling toward the $285.00 level. On the Nasdaq, bulls need a reclaim of 19,500 to suggest the selloff is stabilising. Any further negative clinical trial news from the biotech space could compound pressure on healthcare-adjacent names across both markets.
Bias
Bearish — CSL and Nasdaq healthcare exposure. Failed drug trials historically trigger sector-wide de-rating as investors reassess clinical risk. Until CSL reclaims $310.00 and the Nasdaq holds 18,800, the path of least resistance remains lower for healthcare-linked names.
Source: Read original article